Main Therapeutic Uses

Andractim is a topical androgen therapy containing dihydrotestosterone (DHT), a potent metabolite of testosterone. It is primarily utilized in specialized endocrinology and urology for conditions where a concentrated androgenic effect is required without the extensive systemic conversion associated with other hormones.

Treatment of Gynaecomastia

One of the primary applications of Andractim is the management of gynaecomastia, a condition characterized by the enlargement of breast tissue in males. This often occurs due to an imbalance between estrogen and androgen levels. By applying DHT topically to the chest area, the therapy aims to increase the local androgen concentration, potentially reducing the glandular tissue without significantly elevating systemic estrogen levels.

Management of Micropenis

In pediatric and adult endocrinology, Andractim may be used to treat micropenis (extremely small penis size relative to age and population norms). This condition is often detected in infancy or at the onset of puberty. The application of DHT cream is intended to stimulate the growth of the phallus by providing the specific androgen responsible for the development of male external genitalia.

Androgen Deficiency in Specific Contexts

While not a first-line treatment for generalized male hypogonadism, Andractim is sometimes employed in cases of partial androgen insensitivity syndrome or other specific enzyme deficiencies (such as 5-alpha-reductase deficiency). In these instances, providing DHT directly bypasses the body's inability to convert testosterone into its more active form.

Benefits and Mechanism of Action

Targeted Action

Unlike oral or injectable androgens, a topical DHT gel allows for a more localized hormonal influence. This is particularly beneficial in treating conditions like gynaecomastia, where the goal is to address specific tissue changes.

Non-Aromatizable Nature

A significant characteristic of dihydrotestosterone is that it cannot be converted (aromatized) into estrogen by the body. This makes it a distinct therapeutic option for conditions driven by high estrogen-to-androgen ratios, as it provides androgenic support without the risk of further increasing estrogen levels.

Support for Physical Development

By providing the primary hormone responsible for male secondary sexual characteristics, Andractim supports the physiological development of external genitalia and the reduction of estrogen-sensitive tissues in the male body when used under clinical supervision.

Andractim (Androstanolone gel) is officially restricted to specific patient populations as defined by regulatory bodies. Eligibility is determined by a combination of absolute contraindications, age-based limitations, and pre-existing medical conditions.

Eligibility Scope

| Classification | Population or Condition | Status | | :--- | :--- | :--- | | Allowed | Adult males with clinically and biologically confirmed hypogonadism | Permitted | | Contraindicated | Men with carcinoma of the breast or suspected prostate cancer | Prohibited | | Contraindicated | Pregnant or breastfeeding women | Prohibited | | Contraindicated | Patients with hypersensitivity to Androstanolone or any excipient | Prohibited |

Age and Condition-Based Eligibility

| Population Group | Regulatory Status | Restriction Context | | :--- | :--- | :--- | | Pediatric Males (< 18 yrs) | Safety and efficacy not established | Limitation of use for general replacement therapy | | Geriatric Males (> 65 yrs) | Insufficient long-term safety data | Potential risks of cardiovascular disease and prostate cancer | | Severe Organ Insufficiency | Use with caution | Risk of edema (fluid retention) in severe cardiac, renal, or hepatic disease | | Benign Prostatic Hyperplasia | Requires monitoring | Risk for worsening of signs and symptoms |

Interactions with other medicines and products

The interaction profile for Andractim (Androstanolone gel) is primarily defined by its effects on the body's coagulation system, as documented in official regulatory labeling.

Documented Drug-Drug Interaction

The co-administration of Andractim with Vitamin K Antagonists (oral anticoagulant agents) carries a risk of a pharmacodynamic interaction. This type of interaction affects the coagulation and fibrinolytic systems, leading to an officially recognized increased hemorrhagic risk.

• The use of these agents together requires a procedural constraint: the treating physician must perform more frequent control of the International Normalized Ratio (INR) and potentially adjust the dosage of the anticoagulant medication.

Other Documented Interactions and Constraints

Interaction Type	Status in Regulatory Documents
Prohibited Combinations	None explicitly listed as contraindicated.
Metabolic (CYP) or Transporter Effects	No specific metabolic or transporter interactions are documented.
Food and Beverage Interaction	Officially designated as no documented interaction.
Timing Requirements	No mandatory separation rules (e.g., must be separated by X hours) are documented.
Laboratory Test Impact	Androgens may decrease thyroxin-binding globulin levels, resulting in reduced total T4 plasma levels; however, free thyroid hormone levels remain unchanged, indicating no clinical thyroid dysfunction.

This regulatory profile mandates a focus on the procedural management of co-administered oral anticoagulants.

How Andractim Works: Mechanism of Action

Andractim's mechanism is based on the action of androstanolone (dihydrotestosterone, or DHT), a biologically active, naturally occurring androgen. Its activity is defined by three main biological domains.

---

Androgen Receptor Agonism and Genomic Signaling

Androstanolone functions as a direct agonist for the Androgen Receptor (AR), an intracellular protein that functions as a transcription factor. Upon binding, the activated complex moves into the cell nucleus and directly modulates gene expression by binding to DNA. This mechanism initiates signaling sequences that lead to the synthesis of proteins required for virilization (male development) and anabolism (tissue building).

---

Non-Aromatizable Pathway Effect

A key mechanistic distinction is that androstanolone cannot be converted to estrogen (estradiol) by the aromatase enzyme, unlike testosterone. This means its entire biological influence is exerted solely through the androgen-receptor pathway. The compound's high-affinity effects are concentrated on target tissues like the skin and external genitalia without engaging parallel estrogenic signaling.

---

Central Regulatory Feedback

Androstanolone engages the Hypothalamic-Pituitary-Gonadal (HPG) Axis in a negative feedback loop. The resulting high androgen levels signal to the brain to suppress the release of Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH), which consequentially reduces the body's endogenous production of testosterone and estrogen, resulting in a new dominant androgenic state.

Application Principles

Andractim is a topical preparation designed for cutaneous use. The gel is typically applied to clean, dry skin on specific areas as determined by a healthcare provider. Effective use depends on consistent application and allowing the gel to dry completely before the treated area comes into contact with clothing or other individuals.

Handling and Absorption

To facilitate proper absorption, the gel should be spread thinly over the skin surface. It is not intended to be massaged vigorously into the tissue; rather, it should be allowed to air dry naturally. This process usually takes several minutes. Once the gel has dried, the active component begins to be absorbed through the skin layers into the system.

Hygiene and Contact Precautions

Because the gel remains on the skin surface for a period after application, certain hygiene practices are standard:

• Hand Washing: Hands should be thoroughly washed with soap and water immediately after applying the gel to prevent accidental transfer to other parts of the body or to other people.
• Site Protection: Covering the application site with clothing once the gel is dry helps prevent skin-to-skin transfer to others.
• Showering and Swimming: It is generally recommended to wait several hours after application before bathing or swimming to ensure the medication is not washed away before it can be fully absorbed.

Andractim: Recent Clinical Evidence

Evidence for Specialized Use in Pediatric Undervirilization

The research exploring the gel’s use for specialized conditions in younger males, such as micropenis and genital underdevelopment related to hormonal enzyme deficiencies, consists primarily of small-scale observational studies and case series. These studies included pre-pubertal and peri-pubertal children and focused on measuring the change in genital size, typically Stretched Penile Length (SPL), over defined, short-term treatment intervals. Some trials also examined effects on skeletal maturation, though data for these assessments were limited. Long-term effects into adulthood are not yet fully established in this specialized area. Follow-up durations were limited, and there is a lack of large-scale, robust controlled trials to observe comparative evidence against non-treatment or alternative approaches.

---

Evidence for Use in Adult Androgen Deficiency

For adult males with symptoms related to low androgen levels (hypogonadism), the research base is supported by data from the broader class of transdermal androgens. This research base includes multicenter randomized, controlled trials (RCTs). Studies monitored serum hormone concentrations to observe whether levels entered and remained within the physiological range. Research also examined body composition changes, with data showing patterns related to shifts in lean body mass and fat mass over the study periods. Furthermore, studies explored patient-reported outcomes to monitor how sexual function scores and mood parameters were affected during the study periods.

---

Assessment of Long-Term Follow-up and Uncertainty

The consistency of measured outcomes over time has been explored in long-term open-label trials, with observation periods extending beyond three years. The research highlights that patterns related to physical outcomes were observed throughout the monitored duration. However, these studies were not typically blinded or placebo-controlled. Specific comparative evidence for Androstanolone gel versus other androgen delivery methods is limited. Key scientific questions remain regarding the long-term data for major clinical events, such as definitive evidence on prostatic disease progression or cardiovascular event risk. These areas are documented as insufficiently studied and are the subject of ongoing research.

Common questions about Andractim (FAQ)

Q: Is Andractim considered a type of Anabolic Androgenic Steroid (AAS)?

A: The active ingredient in Andractim, Androstanolone, is structurally related to testosterone and is officially classified as both an androgen and an anabolic steroid. This classification reflects its role in promoting masculine characteristics (androgenic effects) and tissue building (anabolic effects).

Q: Is a local skin reaction at the application site a normal or common issue with Andractim?

A: Yes, regulatory safety documents indicate that application site irritation is a commonly documented adverse reaction. Other common skin-related reactions that may occur include developing oily skin and acne, which are associated with the use of this hormonal product.

Q: Does Andractim have a risk of causing fluid retention or swelling (edema)?

A: Official warnings state that edema (fluid retention or swelling) is a serious potential adverse reaction associated with androgen use. This risk is generally highlighted for individuals who have pre-existing severe heart, kidney (renal), or liver (hepatic) conditions.

Q: Can Andractim affect mood, and are mood swings a possible side effect?

A: Yes, common side effects documented in official product information include effects on the central nervous system. These often manifest as changes in mood, such as mood swings, irritability, and nervousness.

Q: Can Andractim affect blood sugar levels, especially for people with diabetes?

A: Studies on this class of medicine indicate that androgens may influence glucose metabolism. Specifically, they may decrease blood glucose levels, which may be associated with a potential change in insulin requirements for diabetic patients.

Q: What do recent studies say about the long-term safety of Andractim?

A: Clinical evidence reviews indicate that data for the long-term safety of Andractim is still considered insufficient for definitive conclusions. Key scientific questions remain regarding the definitive progression of prostatic disease or the long-term cardiovascular event risk over many years of use.

Q: Is there a specific time of day that is recommended for applying Andractim gel?

A: Official administration protocols state that the gel should be applied once daily. While the documents specify the frequency, they do not mandate a specific time of day (such as morning versus evening) for the application of the Dihydrotestosterone gel.

Q: Is it normal to feel a warming sensation or mild irritation when the gel is applied?

A: Experiencing application site irritation is a commonly documented local adverse reaction when using the gel. Although a warming sensation is not explicitly listed, the irritation is related to the topical nature of the product.

Q: How long does the gel take to dry and be fully absorbed after application?

A: Patient instructions recommend that the gel should be allowed to dry for about five minutes before putting on clothes. Official guidance advises that the treated area should not be washed for at least six hours after application to ensure proper absorption.

Q: Can Andractim use contribute to or worsen sleep apnea?

A: Official warnings associated with the androgen class of medications state that sleep apnea may occur or be worsened in individuals using these products. This risk is generally elevated in patients who already have existing risk factors, such as obesity.

Q: Does Andractim interact with corticosteroids or ACTH, potentially increasing fluid retention?

A: Official drug interaction information indicates that using androgens alongside corticosteroids or ACTH may increase the risk of fluid retention (edema). The use of this combination usually involves close monitoring by a healthcare provider.

Q: Can Andractim cause or worsen male breast enlargement (gynecomastia)?

A: Andractim's active ingredient is a non-aromatizable androgen, meaning it cannot be converted into the hormone estrogen. While this characteristic is a distinction from testosterone, the risk of male breast enlargement (gynecomastia) may still occur as a possible class effect.

Q: Why do some men experience changes in sexual function or libido while on Andractim?

A: The general purpose of this medication is to influence androgenic signaling, which plays a vital role in regulating masculine characteristics, including sexual function and libido. Clinical studies monitor patient-reported outcomes on these functions to assess the drug's therapeutic impact.

Q: Is it true that Andractim is also used for hormone deficiencies in children?

A: Dihydrotestosterone gel is primarily used in specialized contexts in pediatric patients, such as to treat conditions like micropenis or to induce a mini-puberty in babies with certain hormonal issues. However, its use for general, non-specific hormone replacement therapy in children is not officially established.

Q: Are there any specific storage requirements for the Andractim gel (e.g., temperature, light)?

A: Yes, official patient information requires that the gel be stored at room temperature, away from direct light or high heat. It must also be kept from freezing to ensure the medication remains stable and effective.

Q: Does Andractim impact fertility or sperm count?

A: Androgens suppress the body's endogenous hormone production via the HPG axis (the hormonal regulatory system). This suppression may potentially impact fertility and sperm count.

Q: How does the local effect of the gel application differ from the systemic effects?

A: Local effects are those occurring directly at the application site, such as skin irritation and acne. Systemic effects are those that occur throughout the body after the active ingredient has been absorbed, such as mood changes, changes in PSA levels, or polycythemia (increased red blood cell count).

Q: Can Andractim affect existing skin conditions like acne or oily skin?

A: Since acne and oily skin are common adverse reactions documented for Andractim, the drug has the potential to influence the skin. Therefore, it may cause or worsen existing skin conditions related to oil production.

Q: Is there a specific period of time after application before washing the area is safe?

A: Yes, to ensure the active ingredient is properly absorbed through the skin, official guidelines recommend that you avoid washing the application area for at least six hours after you have applied the gel.

Q: How does Andractim's mechanism avoid some of the side effects seen with other androgens?

A: Andractim's active ingredient is a non-aromatizable androgen. This means that unlike testosterone, it cannot be converted into the hormone estrogen. This key mechanistic difference helps to avoid the estrogen-related side effects seen with other androgens.

Q: Are there any studies comparing Andractim to injectable forms of testosterone?

A: While there is a general research base for all transdermal androgens, official reports indicate that specific comparative evidence for Androstanolone gel versus other delivery methods, including testosterone injections, is currently limited.

Q: Is it normal for some hair to grow at the application site?

A: Official safety documents list extra hair growth and general hair changes as common adverse reactions associated with the use of the gel. This effect is related to the drug's androgenic activity.

Q: What are the potential signs of using too high a dosage of Andractim?

A: Regulatory documents list symptoms that may be signs of a potentially high dosage or overdose, including changes such as: excessive energy, mood swings/irritability, noticeable hoarseness, oily skin, acne, or weight gain.

Q: What are the typical non-hormonal ingredients in the Andractim gel formulation?

A: The gel formulation is a hydroalcoholic base containing the active ingredient. The common non-hormonal ingredients, or excipients, used include Carbomer 934, triethanolamine, and a high concentration of Alcohol (95%).

How to Store and Dispose of Andractim?

The official regulatory guidance defines specific conditions for the storage and disposal of Andractim (dihydrotestosterone topical gel) to maintain its stability and prevent accidental exposure.

Storage and Handling Requirement	Official Regulatory Statement
Temperature & Protection	Store at room temperature, protected from direct light or heat.
Container Security	Keep the container tightly closed and in its original packaging.
Flammability Warning	The gel is flammable until dry; keep it away from fire or sources of ignition.
Child Safety	Must be stored out of the reach and sight of children.
Disposal Instructions	Unused or expired product must be returned to the pharmacist for proper, regulated disposal; do not discard in household waste.